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The novel antifolate CB3717 (N10-propargyl-5,8-dideazafolic
acid) has proved to be a potent inhibitor of thymidylate
synthetase (TS) (Jones et al., 1981), the enzyme providing the
de novo synthesis of thymidylate (dTMP) from uridylate
(dUMP). Distinct antiproliferative activity of the drug has
been observed in L1210 ascites tumour (Jones et al., 1981)
and in human hepatoma xenografts (Curtin et al., 1986). A
phase I trial has revealed that side effects in man consists
mainly of hepatotoxicity and renal dysfunction, the latter
limiting the maximal applicable dose to 600mgm-2 (Calvert
et al., 1986).
A specific benefit of the drug is the absence of effect on
purine synthesis, which possibly reduces toxic side effects.
Moreover CB3717 does not need metabolic activation,
making it less vulnerable to certain forms of drug resistance.
In this study the chemotherapeutic activity of CB3717 was
investigated in the Brown Norway myeloid leukaemia
(BNML) and compared with 5-fluorouracil (5-FU). This
pyrimidine analogue has proved to be a potent inhibitor of
TS, although its effect on cell proliferation is also related to
incorporation into DNA and RNA. Moreover the
antitumour effects of both drugs were correlated with their
in vitro inhibition of TS activity.
Properties of the BNML have been described before and
this rat leukaemia is considered to be a reliable model for
experimental chemotherapy (Hagenbeek et al., 1977). Briefly,
rats were injected i.v. with 107 leukaemic cells which, after
progressive leukaemic infiltration of bone marrow, liver and
spleen lead to death in 20-24 days. Increases of spleen and
liver weight have proved to be reliable indicators of
leukaemic growth. In the present study antileukaemic effects
were evaluated by these parameters 18 days after transfer of
leukaemia. Rats were sacrificed by exsanguination and liver
and spleen removed and weighed. Liver and kidneys were
macroscopically inspected in order to assess possible toxic
effects of treatment. Peripheral leucocytes were counted
electronically.
CB3717, kindly provided by ICI Pharmaceuticals
(Macclesfield, UK), was dissolved in 0.15MNaHCO3, pH9.
Both CB3717 and 5-FU (Hoffmann-La Roche) were
administered on day 9, 12 and 16 after leukaemic transfer or
on 5 consecutive days, starting on day 9 in the case of the 5
day protocol.
In one experiment a leukaemic cell suspension (5 x 106
cells ml-1) in Hanks balanced salt solution was prepared
from 2 massively infiltrated spleens. One hundred Mil aliquots
of this suspension were preincubated with various
concentrations of CB3717 or 5-FU for 1 h and subjected to
the deoxyuridine (dU) suppression test (Matthews and
Wickramasinghe, 1986). The incorporation of 3H-thymidine
into DNA with or without dU (0.3 mM) is measured over
1 h. The 1 h preincubation with dU reduces 3H-thymidine
incorporation if its metabolite dUMP can be converted to
dTMP through TS; impaired activity of the latter enzyme
will reduce this suppressive effect of dU on 3H-thymidine
incorporation. The test has proved to be a useful tool for the
measurement of drug activity directed at impaired de novo
dTMP synthesis (Bruckner et al., 1975, Kroes et al., 1986).
In the first series of experiments, leukaemic rats were
treated with 10-30mg CB3717kg-1 body wt. as currently
used in human phase II trials (Cantwell et al., 1986). Table I
shows that no antileukaemic effect of the treatment
schedules was apparent and that signs of toxicity were not
present. On increasing the doses of CB3717 to 100-
125mgkg-1 body wt., levels that exhibit therapeutic activity
in the L1210 leukaemia (Jones et al., 1981), severe weight
loss and increased water consumption, were observed.
Finally death of all treated animals on day 17 or 18 of
leukaemia occurred, which is just before the assigned time of
evaluation. Autopsy revealed some reduction of spleen and
liver weights through treatment but macroscopic visible
granulation and discolouring of liver and kidneys, -probably
due to toxicity, were also noticed. As toxicity of CB3717 is
possibly related to its peak plasma levels (Alison et al., 1985;
Newell et al., 1982), the route of administration was changed
from the bolus i.v. to the i.p. route. Table I shows that with
3 x O00mg or 5 x 75mg CB3717 i.p. fewer toxic deaths did
indeed occur and that antitumour effects were even slightly
enhanced. However, inspection of the intraperitoneal cavity
showed evident precipitation of the drug. Consequently,
further escalation of the dose CB3717 by this route of
administration to improve treatment, was useless.
Compared to CB3717, the pyrimidine analogue 5-FU,
administered 3 x 25 mgkg1 body wt., showed a remarkable
antileukaemic effect resulting in almost normal values of the
studied parameters without any sign of toxicity as previously
described (Ermens et al., 1986).
Because CB3717 and 5-FU both interfere primarily with
TS activity, their varying inhibition of leukaemic growth
may be reflected in a different potency to change the dU
suppression value of leukaemic cells in vitro. Figure 1 shows
that the lowest concentration of 5-FU tested (3.3gm) already
strongly increased incorporation of 3H thymidine into DNA
in the presence of dU. With CB3717 a similar effect could
only be achieved with drug concentrations in the millimolar
range.
The present study thus shows a remarkable parallelism
between the antileukaemic potential of CB3717 and 5-FU in
vivo and their influence on in vitro dTMP synthesis as
measured in the dU suppression test.
The reason for the relatively limited in vivo benefit of high
doses of CB3717 on the BNML is unclear. Other studies
have revealed that inhibitory effects of CB3717 on DNA
synthesis and cell proliferation develop slowly (Simpson &
Harris, 1985) or require higher concentrations (Jackman et
al., 1986) compared to 5-FU. It is possible that limited
cellular uptake of the antifolate partly accounts for this.
Pharmacokinetic studies in mice have shown that i.p.
administration of 100mg CB3717kg-1 body wt. results in
peak plasma levels of 1.3 x l0-4 M (Newell et al., 1986).
Figure 1 shows that CB3717 affects de novo dTMP synthesis
after 3h of in vitro incubation in this concentration range.
However in vivo plasma levels of the drug decline to 10-6M
within 24h of administration (Newell et al., 1986). So the
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Table I Therapeutic effects of CB3717 and 5-fluorouracil (5-FU)
Peripheral
Number Number of Liver weight Spleen weight leukocytes
Treatment (mgkg 1) ofrats toxic deaths (g±s.e.m.) (g +s.e.m.) (1091-1 +s.e.m.)
None (controls) 10 0 16.82+0.60 4.18+0.13 24+2.6
CB3717 3 x 10 i.v. 5 0 16.10+0.43 3.75+0.21 23 +2.2
CB3717 3 x 20 i.v. 4 0 16.44+0.23 3.66+0.17 20+1.3
CB3717 3 x 30 i.v. 3 0 19.74+1.31 4.31+0.40 20+1.7
CB3717 3 x 100 i.v. 4 4 14.77 +0.48 3.59+0.30 -
CB3717 3x 125 i.v. 4 4 13.92+0.37 3.23+0.19 -
CB3717 3 x 100 i.p. 6 1 13.57+0.35 2.66+0.12 11+1.0
CB3717 5x75 i.p. 4 1 11.12+1.83 3.21+0.36 13.2+2.4
5-FU 3 x 25 i.p. 9 0 9.02+0.99 0.90+0.19 5.7+0.8
Normal BN-rats 16 - 8.25+0.24 0.45+0.02 3.9+0.4
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Figure 1 3H-thymidine incorporation into DNA in the presence of
dU as a percentage of values without dU. One hour preincu-
bation with 5-FU: A, one hour preincubation with CB3717: *.
exposure of the leukaemic cells to drug levels necessary for
sustained TS inhibition, is probably limited. Thus the inef-
fective action of CB3717 on the rat leukaemia studied
apparently results from its retarded effect on the target
enzyme TS (relative to 5-FU) in combination with a
relatively rapid plasma clearance.
The efficacy of CB3717 on the L1210 leukaemia growing
i.p. as reported by Jones et al. (1981) can likewise be related
to the i.p. administration of the drug which results in specific
exposure of the leukaemic cells to high concentrations of
CB3717. The observed formation of polyglutamate
derivatives of this antifolate in L1210 cells (Sikora et al.,
1986), enhancing its cellular retention and activity (Cheng, et
al., 1985) may also contribute to the therapeutic success of
CB3717 in this mouse leukaemia model. From the present
study it can be concluded that further preclinical
investigations with CB3717 are necessary before this drug
can be submitted to trials in human haematological
malignancies. In this context, the recent introduction of the
2-desamino derivative of CB3717, which has proved to cause
less renal and hepatic toxicity (Jackman et al., 1987), may
contribute to improvement of the therapeutic index of this
novel antifolate.
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